This week, we’re reading about the lack of preferred Medicare pharmacies in many communities, PBMs’ failed effort to challenge a fiduciary law in California, and a vote by an advisory committee to the FDA encouraging the agency to allow pharmacies to compound peptides for patients with prescriptions.
- Pharmacy Times: Advancing the Future of Independent Pharmacy: Highlights From RBC 2026 (press release, Cardinal Health)
- Healio: Pharmacies provide cognitive screenings, coordinate dementia care
- Politico: FDA advisers endorse legal path for peptides
- Endpoints News: FDA offers updated guidance for generics of weight loss blockbusters
- Becker’s Hospital Review: 1 in 3 communities lack preferred Medicare pharmacies: 4 study notes
- Pharmacy Times: Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
- Vitamin Rush: FDA peptide panel raises questions about future dietary supplement pathway
- Bloomberg Law: PBMs Lose Challenge to California Fiduciary Duties Law (1)
- KLFY: New law changes costs for local pharmacy prescriptions
- WCAX: Local pharmacies to offer flu, strep and COVID testing and treatment under new law
- Minnesota Star Tribune: The FDA may make peptides more available. Minnesota pharmacies are getting ready.
NCPA
